Sutro Biopharma PE Ratio 2017-2022 | STRO
Current and historical p/e ratio for Sutro Biopharma (STRO) from 2017 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Sutro Biopharma PE ratio as of January 27, 2023 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Sutro Biopharma PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2023-01-27 |
7.50 |
|
0.00 |
| 2022-09-30 |
5.55 |
$-2.59 |
0.00 |
| 2022-06-30 |
5.21 |
$-2.89 |
0.00 |
| 2022-03-31 |
8.22 |
$-2.47 |
0.00 |
| 2021-12-31 |
14.88 |
$-2.29 |
0.00 |
| 2021-09-30 |
18.89 |
$-2.94 |
0.00 |
| 2021-06-30 |
18.59 |
$-1.82 |
0.00 |
| 2021-03-31 |
22.76 |
$-0.75 |
0.00 |
| 2020-12-31 |
21.71 |
$-0.93 |
0.00 |
| 2020-09-30 |
10.05 |
$-0.09 |
0.00 |
| 2020-06-30 |
7.76 |
$-1.10 |
0.00 |
| 2020-03-31 |
10.20 |
$-2.64 |
0.00 |
| 2019-12-31 |
11.00 |
$-2.42 |
0.00 |
| 2019-09-30 |
9.09 |
$-1.78 |
0.00 |
| 2019-06-30 |
11.38 |
$-22.48 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.430B |
$0.062B |
|
Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in South San Francisco, California.
|
